Reducing mortality with device therapy in heart failure patients without ventricular arrhythmias

American Journal of Critical Care

Volumn 17, Issue 5, 2008, Pages 443-452

  Chapa, Deborah W ^a   Lee, Hyeon Joo ^e   Kao, Chi Wen ^c   Friedmann, Erika ^e   Thomas, Sue A ^b   Anderson, Jill ^e   Bardy, Gust H ^d  

^a FLORIDA GULF COAST UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF NURSING   (United States)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d Seattle Institute for Cardiac Research   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT;

ARTIFICIAL HEART PACEMAKER; DEFIBRILLATOR; HEART FAILURE; HUMAN; INTENSIVE CARE; MORTALITY; NURSE ATTITUDE; PATIENT EDUCATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; SUDDEN DEATH;

CARDIOVASCULAR AGENTS; CRITICAL CARE; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE; HUMANS; NURSE'S ROLE; PACEMAKER, ARTIFICIAL; PATIENT EDUCATION AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 58149132440     PISSN: 10623264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. American Heart Association. Heart Disease and Stroke Statistics-2006 Update. Dallas, TX: American Heart Association; 2006.
2. MERIT-HF study group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999; 353(9169):2001-2007.
3. Cohn JN. Prognosis in congestive heart failure. J Card Fail. 1996;2(4 suppl):S225-S229.
4. Cowburn PJ, Cleland JG, Coats AJ, Komajda M. Risk stratification in chronic heart failure. Eur Heart J. 1998;19(5):696-710.
5. Smith WM. Epidemiology of congestive heart failure. Am J Cardiol. 1985;55(2):3A-8A.
6. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death: structure, function, and time-dependence of risk. Circulation. 1992;85(1 suppl):I2-I10.
7. Myerburg RJ, Interian A Jr, Mitrani RM, Kessler KM, Castellanos A. Frequency of sudden cardiac death and profiles of risk. Am J Cardiol. 1997;80(5B):10F-19F.
8. Bubien RS, Ching EA, Kay GN. Cardiac defibrillation and resynchronization therapies: principles, therapies, and management implications. AACN Clin Issues. 2004;15:340-361.
9. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet. 1994;344(8921):493-498.
10. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure [published correction appears in N Engl J Med. 2005;352(20):2146]. N Engl J Med. 2005;352(3):225-237.
11. Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004;350(21):2140-2150.
12. Cleland JG, Daubert JC, Erdmann E, et al; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352(15):1539-1549.
13. Woods SL, Sivarajan Froelicher E, Underhill Motzer S, Bridges EJ, eds. Cardiac Nursing. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
14. Heart Failure Society of America. The stages of heart failure: NYHA classification. http://www.abouthf.org/questions_stages.htm. September 26, 2006. Accessed June 16, 2008.
15. Freudenberger R, Sikora JA, Fisher M, Wilson A, Gold M. Electrocardiogram and clinical characteristics of patients referred for cardiac transplantation: implications for pacing in heart failure. Clin Cardiol. 2004;27:151-153.
16. Kearney MT, Zaman A, Eckberg DL, et al. Cardiac size, autonomic function, and 5-year follow-up of chronic heart failure patients with severe prolongation of ventricular activation. J Card Fail. 2003;9:93-99.
17. Friedman LM, Furberg CD, DeMets DL. Fundamentals of Clinical Trials. 3rd ed. New York, NY: Springer; 2006.
18. Anderson J, Bardy GH. Key clinical insights from the Sudden Cardiac Death in Heart Failure Trial. J Cardiovasc Nurs. 2006; 21(6):463-468.
19. Moss AJ, Brown M, Cannon DS, et al. Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT): design and clinical protocol. Ann Noninvasive Electrocardiol. 2005;10(4 suppl):34-43.
20. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005;112(12):e154-e235.
21. Centers for Medicare and Medicaid Services. Medicare expands coverage of implantable defibrillators to save lives and develop evidence to maximize benefits [press release]. http://www.cms.hhs.gov/apps/media/press/release.asp?Counter=1331. Published January 27, 2005. Updated May 14, 2007. Accessed May 26, 2008.
22. Alter P, Waldhans S, Plachta E, Moosdorf R, Grimm W. Complications of implantable cardioverter defibrillator therapy in 440 consecutive patients. Pacing Clin Electrophysiol. 2005;28(9):926-932.
23. Reynolds MR, Cohen DJ, Kugelmass AD, et al. The frequency and incremental cost of major complications among Medicare beneficiaries receiving implantable cardioverterdefibrillators. J Am Coll Cardiol. 2006;47(12):2493-2497.
24. Gradaus R, Breithardt G, Bocker D. ICD leads: design and chronic dysfunctions. Pacing Clin Electrophysiol. 2003;26: 649-657.
25. Niu HX, Hua W, Wang FZ, Zhang S, Chen KP, Chen X. Complications of cardiac resynchronization therapy in patients with congestive heart failure. Chin Med J (Engl). 2006; 119(6):449-453.
26. Sweesy MW, Holland JL, Smith KW. Electromagnetic interference in cardiac rhythm management devices. AACN Clin Issues. 2004;15:391-403.
27. US Food and Drug Administration, Center for Devices and Radiological Health. Electromagnetic compatibility-cellular phone interference: update on cellular phone interference with cardiac pacemakers. http://www.fda.gov/cdrh/emc/pace .html. Published November 1, 1995. Updated September 10, 1997. Accessed May 26, 2008.
28. Stone KR, McPherson CA. Assessment and management of patients with pacemakers and implantable cardioverter defibrillators. Crit Care Med. 2004;32(4 suppl):S155-S169.
29. Mark DB, Nelson CL, Anstrom KJ, et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation. 2006;114(2):135-142.
30. Goldberger Z, Lampert R. Implantable cardioverter-defibrillators: expanding indications and technologies. JAMA. 2006;295:809-818.